Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000010594
Ethics application status
Approved
Date submitted
14/10/2023
Date registered
10/01/2024
Date last updated
21/06/2024
Date data sharing statement initially provided
10/01/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Noninvasive vagal nerve stimulation for abdominal symptoms in people with spinal cord injury
Scientific title
Noninvasive transcutaneous vagal nerve stimulation for abdominal symptoms in people with spinal cord injury
Secondary ID [1] 309353 0
Nil known
Universal Trial Number (UTN)
U1111-1299-0557
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Abdominal pain
 329560 0
spinal cord injury 332005 0
Condition category
Condition code
Oral and Gastrointestinal 326489 326489 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Musculoskeletal 328739 328739 0 0
Other muscular and skeletal disorders
Physical Medicine / Rehabilitation 328740 328740 0 0
Other physical medicine / rehabilitation
Neurological 328741 328741 0 0
Other neurological disorders
Injuries and Accidents 328742 328742 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Transcutaneous vagal nerve stimulation delivered by a hand-held device around the neck
-gammaCore(Transcutaneous VNS device) is a size of the card deck and is battery operated. It produces an electrical signal that consists of five 5000 Hz pulses. This pulse is repeated at a rate of 25 Hz. The waveform produced by this device is approximately sign wave.
-Initial stimulation will be delivered by nursing staff/doctor involved in study.
-Participants will deliver 2 minutes of stimulation on each side of the neck (total 4 minutes) twice a day (total 8 minutes). Participants will be instructed to look for the slight twitch at the periphery of the neck to ensure delivery of sufficient voltage delivery. (as per device manufacturer's recommendation)
-Participants are to complete the treatment diary to record the stimulations delivered


Visit schedules
-The participant will complete baseline questionnaire prior to the first visit : This will assess participant’s medical history including nature of spinal cord injury, bowel function, picture map of abdominal pain, character of the pain, non-abdominal pain, quality of life questions, hospital anxiety and depression questionnaire and Rome questionnaire for disorders of gut-brain interaction.
-During the first visit : The participant will complete ECG and routine observations. These will be completed by either nurses/doctors involved in clinical trial. They may also receive abdominal x-ray and abdominal ultrasound. X-ray will be done at hospital radiology department. Ultrasound may be done at bed side by the doctor involved in this study.
-After this, the participant will undergo the first stimulation. First stimulation will be same in duration as routine as described above.
If the first stimulation is successful, a participant (or carer) will be educated about how to use the VNS device and given a device to take home. Education will be done by the nurse/doctor involved in this clinical trial and will be approximately 15-30 minutes
-The participant will continue to deliver stimulation as per above schedule and will be asked to keep the diary
-The participant also have to complete the ‘progress questionnaire’ at week 4, week 8 and week 12. The progress questionnaire consists of questions addressing abdominal pain location (using a diagram), severity of abdominal pain, number of bowel motions, quality of life questions and hospital anxiety and depression score.
- Overall treatment duration will be 12 weeks.
Intervention code [1] 327188 0
Treatment: Devices
Comparator / control treatment
No control group. This is a proof-of-concept pilot study. Participant response before and after the treatment will be compared.
Control group
Active

Outcomes
Primary outcome [1] 334332 0
Pain scale - Ten point visual analogue scale
Timepoint [1] 334332 0
Assessed using at week 0, 4, 8 and 12. Ten point visual analogue was designed based from international spinal cord injury pain basic data set/ bowel function data set.
Primary outcome [2] 336552 0
Abdominal pain map - Participant marks locations of the pain on diagram of abdomen/back
Timepoint [2] 336552 0
Assessed using online questionnaire at week 0, 4, 8 and 12. This online interactive abdominal pain map was developed specifically for this study.
Secondary outcome [1] 420279 0
Colonic motility
Timepoint [1] 420279 0
Assessed using abdominal x-ray after consuming oral contrast marker(Eg. Sitzmark) at week 0 and 12
Secondary outcome [2] 428794 0
Autonomic dysreflexia
Timepoint [2] 428794 0
Patients will be asked if they had autonomic dysreflexia event at 0, 4, 8 and 12. No specific pre-validated questionnaire was used.
Secondary outcome [3] 428795 0
Quality of life using ten point visual analogue scale.
Timepoint [3] 428795 0
Assessed using at week 0, 4, 8 and 12. Ten point visual analogue was designed based from international spinal cord injury pain basic data set/ bowel function data set.

Eligibility
Key inclusion criteria
Patients with spinal cord injury for at least 12 months
Currently experiencing abdominal symptoms, including abdominal pain/discomfort
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unable to complete questionnaires – whether due to impaired cognition or language barrier
Unable to deliver vagal nerve stimulation by him/herself OR does not have someone else who can deliver the VNS
Unable to attend required face-to-face visits
Any other implant device that may interfere with vagal nerve stimulation
Underlying significant cardiac abnormality, especially cardiac arrhythmia
(Relative contraindication) History of recurrent or severe autonomic dysreflexia

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/08/2024
Actual
Date of last participant enrolment
Anticipated
31/05/2026
Actual
Date of last data collection
Anticipated
30/06/2026
Actual
Sample size
Target
15
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 24442 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 40023 0
2065 - St Leonards

Funding & Sponsors
Funding source category [1] 313553 0
Hospital
Name [1] 313553 0
Royal North Shore Hospital
Country [1] 313553 0
Australia
Primary sponsor type
Hospital
Name
Royal North Shore Hospital
Address
Reserve Rd St Leonards NSW 2065
Country
Australia
Secondary sponsor category [1] 317035 0
None
Name [1] 317035 0
Address [1] 317035 0
Country [1] 317035 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 312734 0
The Northern Sydney Local Health District Human Research Ethics Committee (NSLHD HREC)
Ethics committee address [1] 312734 0
Ethics committee country [1] 312734 0
Australia
Date submitted for ethics approval [1] 312734 0
Approval date [1] 312734 0
21/07/2023
Ethics approval number [1] 312734 0
2023/ETH00832 and 2023/STE01288

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 125714 0
Prof Allison Malcolm
Address 125714 0
Level 4 Gastroenterology Unit Royal North Shore Hospital Reserve Rd St Leonards NSW 2065
Country 125714 0
Australia
Phone 125714 0
+61 2 9462 9640
Fax 125714 0
Email 125714 0
[email protected]
Contact person for public queries
Name 125715 0
Calvin Park
Address 125715 0
Level 4 Gastroenterology Unit Royal North Shore Hospital Reserve Rd St Leonards NSW 2065
Country 125715 0
Australia
Phone 125715 0
+61 2 9462 2460
Fax 125715 0
Email 125715 0
[email protected]
Contact person for scientific queries
Name 125716 0
Allison Malcolm
Address 125716 0
Level 4 Gastroenterology Unit Royal North Shore Hospital Reserve Rd St Leonards NSW 2065
Country 125716 0
Australia
Phone 125716 0
+61 2 9462 9640
Fax 125716 0
Email 125716 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.